Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ella Clear all

Conditions: Contraception
Interventions: CDB-2914, Levonorgestrel; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 2,221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Los Angeles, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions: SexHealth II, Contraceptive; Behavioral · Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Postmenopause
Interventions: CDB 2914; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions: Ulipristal Acetate; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 51 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Contraception
Interventions: LNG-EC, UPA-EC; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Contraception
Interventions: CDB-2914; Drug
Lead sponsor: Population Council; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endometriosis
Interventions: Ulipristal; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception, Bleeding
Interventions: Ulipristal Acetate, Placebo oral capsule; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Leiomyoma
Interventions: ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Levonorgestrel-based emergency contraception 1.5 mg, Levonorgestrel-based emergency contraception 3.0mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mammography Screening, Breast Density
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate; Procedure · Other · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception
Interventions: Emergency contraception website, Emergency contraception video; Other
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: Ulipristal Acetate 30 MG Oral Tablet; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pregnancy, Unplanned, Pregnancy; Accident
Interventions: Ulipristal acetate, levonorgestrel IUS; Drug · Device
Lead sponsor: Planned Parenthood of the St. Louis Region and Southwest Missouri; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Indianapolis, Indiana • St Louis, Missouri

Conditions: Leiomyoma, Uterine Hemorrhage
Interventions: Ulipristal acetate (UPA), Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 61
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more

Conditions: Emergency Contraception
Interventions: CDB-2914, levonorgestrel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,672 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • New York, New York + 3 more

Conditions: Renal Function
Interventions: Ulipristal acetate; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy
Interventions: Ulipristal Acetate Tablets, Misoprostol Pill; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Hillsborough, North Carolina

Conditions: Contraceptive Usage
Interventions: Ulipristal acetate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pain, Anxiety
Interventions: Jazz music, No music; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions: Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Contraception
Interventions: UPA-ECx1, UPA-ECx2; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Inpatient Adolescent Contraception

Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

EC PK in Women With Normal and Obese BMI

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

Ulipristal for Endometriosis-related Pelvic Pain

Intervention to End Recurrent Unscheduled Bleeding Trial

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG

Mammogram Pretreatment With Ulipristal Acetate

Targeted Video Messaging About Emergency Contraception

On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

Levonorgestrel Intrauterine System For Emergency Contraception

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

Efficacy Trial of CDB 2914 for Emergency Contraception

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Impact of Combined Hormonal Contraceptives on UPA

Ulipristal Acetate for Use in Early Pregnancy Loss

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA